# LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

> **NCT00151697** · PHASE3 · COMPLETED · sponsor: **Rijnstate Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Diabetes Mellitus Type II

## Interventions

- **DRUG:** Novomix 30
- **DRUG:** Novorapid and Amaryl
- **DRUG:** Lantus

## Key facts

- **NCT ID:** NCT00151697
- **Lead sponsor:** Rijnstate Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2011-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151697, "LANN-study: Lantus, Amaryl, Novorapid, Novomix Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00151697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*